Harnessing Nanomedicine to Potentiate the Chemo-Immunotherapeutic Effects of Doxorubicin and Alendronate Co-Encapsulated in Pegylated Liposomes is a research paper published in Pharmaceutics (2023). On theSindex it has a DataRank of 0. It has been cited 5 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Levco Pharmaceuticals Ltd.
Grant: EP/S032789/1
Next generation molecular imaging and therapy with radionuclides
Levco Pharmaceuticals Ltd.
Grant: WT 203148/Z/16/Z
Levco Pharmaceuticals Ltd.
Grant: 212885/Z/18/Z
Levco Pharmaceuticals Ltd.
Grant: IS-BRC-1215-20006
Levco Pharmaceuticals Ltd.
Grant: CA282339
Wellcome Trust
Grant: 203148/Z/16/Z
NCI NIH HHS
Grant: R01 CA282339
National Institutes of Health
Grant: 5R01CA282339-03
CHOLESTEROL METABOLISM IN THE PHARMACOLOGY OF LIPOSOMAL THERAPEUTICS
Wellcome Trust
Grant: 212885
A multiuser radioanalytical facility for molecular imaging and radionuclide therapy research
Wellcome Trust
Grant: 203148
King's College London Medical Engineering Centre of Research Excellence
Levco Pharmaceuticals Ltd.
Medical Research Council Confidence in Concepts award
Wellcome Trust
Experimental Cancer Medicine Centre at King’s College London
FWCI
0.77
Citation Percentile
0.7%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals